Study finds hope for oral hepatitis C regimen

01/19/2012 | Bloomberg

A study published in the New England Journal of Medicine found that 36% of hepatitis C patients who took the oral drug candidates daclatasvir and asunaprevir had undetectable viral loads after 24 weeks. Meanwhile, nine in 10 patients responded to the combination plus ribavirin and interferon. This is the first study to indicate that difficult-to-treat cases might respond without the aid of injectable interferon, said the lead researcher.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR